MediWound Ltd.

www.mediwound.com

High-Tech Company
Public Company

(NASDAQ GM: MDWD)

TECH VERTICALS

Biopharmaceuticals, Biotechnology, Chronic Wounds Treatment, Life Sciences, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	2000
Number of Employees	120
Employees in Israel	90
Reg. Number:	abCDe

DESCRIPTION

MediWound is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

TECHNOLOGY

Proprietary proteolytic enzyme platform (bromelain-based).

Products and Phases

Product	Phase
NexoBrid®	FDA Approved CE Approved EMA, Israel, Japan
A topically applied biologic that enzymatically removes burn eschar while preserving healthy tissue offering a less invasive alternative to surgery. Approved in over 40 countries, including the U.S., EU, and Japan, it transforms burn care by promoting faster healing and reducing complications in both adult and pediatric patients.
MW005	Phase II
A topical biological drug for the treatment of non-melanoma skin cancers. Phase I/II study in low-risk basal cell carcinoma (BCC).
EscharEx®	Phase III
A topical, enzymatic therapy in late-stage development for the debridement of chronic and hard-to-heal wounds. Designed for easy daily application, it offers a non-surgical approach to wound bed preparation by removing non-viable tissue, reducing bioburden, and promoting healing. Currently being evaluated in a global Phase III study for venous leg ulcers, with additional studies planned for diabetic foot ulcers.

ESTIMATED ANNUAL SALES

Year	Amount
2024	500
2023	490
2022	480
2021	470
2020	460
2019	450
2018	440
2017	430
2016	420
2015	410

	TARGET MARKETS
	Plastic Surgery & Burn Clinics, Public health agencies, Patients with burns and chronic wounds (e.g. diabetic foot ulcers), and basal cell carcinoma.

	BUSINESS MODEL
	B2B

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm

CONTACT INFO

Expand / Collapse All

Main Address: Yavne, Israel

Address	42 Hayarkon St.
City	Yavne
Country	Israel
Zip	8122745

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Wilmington, United States

Address	1007 North Organe St.
City	Wilmington
State/Province	DE
Country	United States
Zip	19801

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Russelsheim, Germany

Address	100 Hans-Sachs-Str.
City	Russelsheim
Country	Germany
Zip	65428

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Italy

Country	Italy

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Spain

Country	Spain

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: United Kingdom

Country	United Kingdom

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Romania

Country	Romania

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Poland

Country	Poland

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Ofer Gonen	CEO	Cactus Acquisition Corp. 1 (CEO)
Dr. Ety Klinger	Chief R&D Officer	KREC (Mentor)
Dr. Shmulik Hess	COO & Chief Commercial Officer
Ms. Hani Luxenburg	CFO	BIRD Aerosystems (CFO)
Dr. Robert Snyder	Chief Medical Officer
Mr. Yaron Meyer	EVP & General Counsel & Corporate Secretary
Mr. Barry Wolfenson	EVP, Strategy & Corporate Development
Ms. Hagit Mashiach-Alon	VP, HR	Amobee (HR Director EMEA)
Mr. Marian Gorecki	Co-Founder	Polyheal (Clinical Advisor)
Prof. Lior Rosenberg	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Chairman, Cactus Acquisition Corp
abC Defghij	Board Member	CFO & COO, Palatin Technologies
abC Defghij	Board Member	Chairman, Trima Pharma
abC Defghij	Board Member	President & Chair, Wound Care Collaborative Community (WCCC)
abC Defghij	Board Member	Founder & Managing Partner, David Fox & Co LLC

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Sep. 02, 2013

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe	CBI realized the option to buy Teva's shares in MediWound. The payment will be the equivalent of 20% of MediWound's income from selling its and/or Polyheal's products or the license to them, up to $43m. CBI now holds 63% of the company.

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Feb. 03, 2023	Fifth Public Offering	NASDAQ GM	abCDe	abCDe	Registered Direct Offering; Participants include American institutional investors, aMoon Fund, IBF Fund and Deep Insight Fund.
Sep. 22, 2022	Fourth Public Offering	NASDAQ GM	abCDe	abCDe	Registered Direct Offering
Mar. 03, 2022	Third Public Offering	NASDAQ GM	abCDe	abCDe	$1.2m from partial exercise by the underwriters of their over-allotment option (green shoe option).
Sep. 21, 2017	Second Public Offering	NASDAQ GM	abCDe	abCDe	Including Green Shoe Option ($3.2m).
Mar. 20, 2014	IPO	NASDAQ GM	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Jul. 16, 2024

Revenue Growth

abCDe

PIPE

Jul. 15, 2024

Revenue Growth

abCDe

PIPE

Sep. 22, 2022

Revenue Growth

abCDe

Fifth Round

Aug. 20, 2013

R&D

abCDe

Buyout

Dec. 30, 2010

R&D

abCDe

Fourth Round

Dec. 30, 2010

R&D

abCDe

Buyout

Jun. 20, 2007

R&D

abCDe

Third Round

Jun. 20, 2007

R&D

abCDe

Second Round - Extended

Dec. 28, 2006

R&D

abCDe

Second Round

May. 09, 2006

R&D

abCDe

First Round

Mar. 03, 2002

R&D

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jul. 16, 2024

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe	€2.5m

R&D Grant

Dec. 28, 2023

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Other	abCDe	Through The Medical Technology Enterprise Consortium.

R&D Grant

Feb. 10, 2022

Revenue Growth

abCDe

As of December 31, 2021, the company has received approximately $70m (out of $91m committed) in funding, in the aggregate, from BARDA under the two contracts to support development activities and an additional $14.6m for procurement of NexoBrid. The cumulative, non-dilutive funding under both contracts with BARDA is now valued at up to $211m. It includes additional options to fund development of other potential NexoBrid indications, and an option to procure additional NexoBridAs.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Mar. 03, 2020

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

May. 29, 2019

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jul. 19, 2017

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Sep. 30, 2015

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Oct. 01, 2000

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Mar. 01, 2000

Seed

Contributor	Type	Amount	Remarks
abC Defghij	Technology Transfer Company	abCDe	Holds 2% of the company

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Polyheal

Biomed

Fourth Round

30/12/2010

N/A

$6.8m

Purchased 7.5% of the company from existing shareholders as a first phase of a series of agreements with Teva Pharmaceutical Industries and PolyHeal to collaborate in the development, manufacturing and commercialization of PolyHeal's wound product. In December of 2012 Teva and Mediwound decided to revoke the agreements between them. 11/2017: Following a legal dispute between Mediwound and Polyheal regarding Mediwound's obligation to uphold phase 2 of the agreements, the Tel Aviv District Court ordered that MediWound is obligated to purchases shares of three shareholders of PolyHeal for approximately $1.5 million. 24/03/2019: Mediwound signed a settlement with Teva which overruled the decision from 2017.

Last Updated:	abCDe
IVC Number:	abCDe